


## Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition of matter of the formula



and multimers thereof, wherein:

$F^1$  is an Fc domain;

$X^1$  and  $X^2$  are each independently selected from  $-(L^1)_c-P^1$ ,  $-(L^1)_c-P^1-(L^2)_d-P^2$ ,  $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$ , and  $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

$P^1$ ,  $P^2$ ,  $P^3$ , and  $P^4$  are each independently randomized EPO-mimetic antagonist peptide sequences;

$L^1$ ,  $L^2$ ,  $L^3$ , and  $L^4$  are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither  $X^1$  nor  $X^2$  is a native protein.


2. (original) The composition of matter of Claim 1 of the formulae




or



3. (original) The composition of matter of Claim 1 of the formula



4. (original) The composition of matter of Claim 1 of the formula



5. (original) The composition of matter of Claim 1 wherein  $F^1$  is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein  $F^1$  is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein  $F^1$  comprises the sequence of SEQ ID NO: 2.

- 8-12. (canceled)

13. (previously presented) The composition of matter of Claim 1 wherein the EPO mimetic peptide sequence is selected from Table 5.
14. (previously presented) The composition of matter of Claim 13~~4~~ wherein F<sup>1</sup> comprises the sequence of SEQ ID NO: 2.
15. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and 41.
16. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 339 and 340.
- 17 - 66 (canceled).